IMLFF News and Press, InMed Pharmaceuticals Inc. From 03/20/20

InMed Pharmaceuticals ( OTCQX:IMLFF ) provides an update on the impact of COVID-19 on its business operations. More news on: InMed Pharmaceuticals Inc., Healthcare stocks news, Read more ...

InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak Canada NewsWire VANCOUVER, March 20, 2020 VANCOUVER , March 20, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical comp...

VANCOUVER , March 10, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of c...

LONDON, UK / ACCESSWIRE / February 20, 2020 / InMed Pharmaceuticals (TSX:IN) recently announced that the first human clinical trial (755-101-HV) of its lead program, INM-755 for the treatment of epidermolysis bullosa (EB), is currently around 50% enrolled with full enrollment expected this q...

The following slide deck was published by InMed Pharmaceuticals Inc. in conjunction with this Read more ...

InMed Pharmaceuticals Inc. (IMLFF) Q2 2020 Earnings Conference Call February 14, 2020 11:30 AM ET Company Participants Brendan Payne - Director of Investor Relations Eric Adams - President & Chief Executive Officer Bruce Colwill - Chief Financial Officer Eric Hsu - Senior V...

InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update Canada NewsWire VANCOUVER, Feb. 14, 2020 ...

InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020 Canada NewsWire VANCOUVER, Feb. 7, 2020 VANCOUVER , Feb. 7, 2020 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a ...

AdaptHealth (NASDAQ: AHCO ) initiated with Buy rating and $17 (31% upside) price target at Stifel. More news on: AdaptHealth Corp., DURECT Corporation, InMed Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more ...

VANCOUVER , Jan. 21, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cann...